Zobrazeno 1 - 8
of 8
pro vyhledávání: '"vasoconstrictor agents adverse effects"'
Autor:
Thomsen, Josefine, Sprogøe, Ulrik
Publikováno v:
Thomsen, J & Sprogøe, U 2019, ' Komplet takyfylaksi for vasopressor hos en patient med subaraknoidalblødning ', Ugeskrift for Laeger, bind 181, nr. 22, V01180050 . < http://ugeskriftet.dk/videnskab/komplet-takyfylaksi-vasopressor-hos-en-patient-med-subaraknoidalblodning >
In this case report, we present a 28-year-old woman who was admitted to a neuro-intensive care unit with subarachnoid haemorrhage. She was intubated and haemodynamically unstable. Over five days the need for norepinephrine reached the level of 1.2 µ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3062::e1b4ffe5735e4edd9d83bb55d8943bcb
https://portal.findresearcher.sdu.dk/da/publications/f3e23ca4-1ec9-4f98-84a9-810c92af0309
https://portal.findresearcher.sdu.dk/da/publications/f3e23ca4-1ec9-4f98-84a9-810c92af0309
Autor:
Rachel W. Winter, Mads Israelsen, Manol Jovani, Alison Goldin, Aleksander Krag, Andrew S. Allegretti, Lise Lotte Gluud
Publikováno v:
The Cochrane Library
Israelsen, M, Krag, A, Allegretti, A S, Jovani, M, Goldin, A H, Winter, R W & Gluud, L L 2017, ' Terlipressin versus other vasoactive drugs for hepatorenal syndrome ', Cochrane Database of Systematic Reviews, vol. 2017, no. 9, CD011532 . https://doi.org/10.1002/14651858.CD011532.pub2
Israelsen, M, Krag, A, Allegretti, A S, Jovani, M, Goldin, A H, Winter, R W & Gluud, L L 2017, ' Terlipressin versus other vasoactive drugs for hepatorenal syndrome ', Cochrane Database of Systematic Reviews, vol. 2017, no. 9, CD011532 . https://doi.org/10.1002/14651858.CD011532.pub2
Background Hepatorenal syndrome is defined as severe renal failure occurring in people with cirrhosis and ascites. Systematic reviews of randomised clinical trials found that, compared with placebo, terlipressin may reduce mortality and improve renal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c851f96fb2261499e33852264bb0f72
https://doi.org/10.1002/14651858.cd011532.pub2
https://doi.org/10.1002/14651858.cd011532.pub2
Autor:
Eugenio Rosset, Bruno Pereira, Jugurtha Aliane, Nader Guesmi, Damien Bouvier, Christian Dualé, Charlotte Baud, Pierre Schoeffler
Publikováno v:
Clinical and Experimental Pharmacology and Physiology-Supplement
Clinical and Experimental Pharmacology and Physiology-Supplement-, 2017, 44 (7), pp.739-748. ⟨10.1111/1440-1681.12759⟩
Clinical and Experimental Pharmacology and Physiology-Supplement-, 2017, 44 (7), pp.739-748. ⟨10.1111/1440-1681.12759⟩
While both ephedrine and phenylephrine are currently used to treat hypotension occurring during carotid endarterectomy (CEA) under general anaesthesia, phenylephrine may have deleterious effects on the cerebral watershed, due to its exclusively vasoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3de833dc4e2418f02f9bb121ddda1f
https://hal.uca.fr/hal-01919746
https://hal.uca.fr/hal-01919746
Autor:
Allison R. Schulman, Andrew S. Allegretti, Alison Goldin, Manol Jovani, Mads Israelsen, Lise Lotte Gluud, Rachel W. Winter, Aleksander Krag
Publikováno v:
The Cochrane Library
Allegretti, A S, Israelsen, M, Krag, A, Jovani, M, Goldin, A H, Schulman, A R, Winter, R W & Gluud, L L 2017, ' Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome ', Cochrane Database of Systematic Reviews, vol. 6, no. 6, CD005162 . https://doi.org/10.1002/14651858.CD005162.pub4
Allegretti, A S, Israelsen, M, Krag, A, Jovani, M, Goldin, A H, Schulman, A R, Winter, R W & Gluud, L L 2017, ' Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome ', Cochrane Database of Systematic Reviews, vol. 6, no. 6, CD005162 . https://doi.org/10.1002/14651858.CD005162.pub4
Background Hepatorenal syndrome is a potentially reversible renal failure associated with severe liver disease. The disease is relatively common among people with decompensated cirrhosis. Terlipressin is a drug that increases the blood flow to the ki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eda84792d2b1feceff11da7f7c001de9
https://doi.org/10.1002/14651858.cd005162.pub4
https://doi.org/10.1002/14651858.cd005162.pub4
Autor:
Israelsen, Mads Egerod, Gluud, Lise Lotte, Bendtsen, Flemming, Krag, Aleksander Ahm, Møller, S.
Publikováno v:
Israelsen, M E, Gluud, L L, Bendtsen, F, Krag, A A & Møller, S 2013, ' Hepatorenalt syndrom : Diagnose, behandling og forebyggelse ', Ugeskrift for Laeger, bind 175, nr. 22, s. 1562-1565 .
Cirrhosis, ascites and renal impairment are associated with high morbidity and mortality. The hepatorenal syndrome (HRS) is a type of renal failure that affects patients with cirrhosis and ascites. This paper provides an update on evidence-based inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3062::097e53c8377c59ca8b89731cdd4b35b2
https://portal.findresearcher.sdu.dk/da/publications/536f95fb-9de9-4a95-8dc5-3eb351bae8f4
https://portal.findresearcher.sdu.dk/da/publications/536f95fb-9de9-4a95-8dc5-3eb351bae8f4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.